Association between proton pump inhibitors and benign non-neoplastic gastric lesions.

Association between proton pump inhibitors and benign non-neoplastic gastric lesions. - Association between proton pump inhibitors and benign non-neoplastic gastric lesions.

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000030144

Enrollment

300

Registered

2017-11-28

Start date

2017-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

benign non-neoplastic gastric lesions

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who undergo magnifying endoscopy. Patients who were over 20 years. Patients who were eligible to this study criteria with written informed consent signed and dated.

Exclusion criteria

Exclusion criteria: Patients who have risk factor of bleeding after biopsy such as receiving anticoagulation therapy. Patients who have lesions which cannot be observed because of erosion, ulcer or bleeding. Patients who have tendency of easy bleeding such as liver cirrhosis, hemophilia or ITP. Patients who have history of distal or gastorectomy. Patients who are not eligible to this study due to psychotic disease or psychological symptoms. Patients whom doctor decide not to register to this study.

Design outcomes

Primary

Measure	Time frame
Associations between the long-term use of PPIs and the occurrence of multiple white flat lesions (MWFL).	—

Secondary

Measure	Time frame
Associations between Vonoprazan (VPZ) and the occurrence of MWFL. Difference in expression of MWFL by type of PPIs and VPZs. Difference in expression of MWFL due to oral administration period of PPIs and VPZs. Associations between the long-term use of PPIs or VPZs and the occurrence of benign non-neoplastic gastric lesions such as foveolar hyperplastic polyps or fundic gland polyps. Features of endoscopic findings (white light, chromoendoscpy, NBI and magnifying NBI imaging) of MWFL. Features of histopathological findings of MWFL. Associations between presence of MWFL and Hypergastrinemia. Associations between presence of MWFL and Helicobacter pylori infection. Associations between presence of MWFL and atrophic changes of gastric mucosa. Associations between the long-term use of H2 receptor antagonists and MWFL.	—

Measure

Time frame

Associations between Vonoprazan (VPZ) and the occurrence of MWFL. Difference in expression of MWFL by type of PPIs and VPZs. Difference in expression of MWFL due to oral administration period of PPIs and VPZs. Associations between the long-term use of PPIs or VPZs and the occurrence of benign non-neoplastic gastric lesions such as foveolar hyperplastic polyps or fundic gland polyps. Features of endoscopic findings (white light, chromoendoscpy, NBI and magnifying NBI imaging) of MWFL. Features of histopathological findings of MWFL. Associations between presence of MWFL and Hypergastrinemia. Associations between presence of MWFL and Helicobacter pylori infection. Associations between presence of MWFL and atrophic changes of gastric mucosa. Associations between the long-term use of H2 receptor antagonists and MWFL.

—

Countries

Japan

Contacts

Public ContactRino Yamaoka

Fukuoka University Chikushi Hospital Endoscopy

rinori1222@yahoo.co.jp092-921-1011

Outcome results